Establishment Labs

ESTA

Market cap $2.29B

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.98 per share a year ago.

Establishment Labs Holdings Inc. (ESTA) Q4 2025 Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided 2026 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $64.6 million, an increase of 45.2% from the year-ago period. 2025 revenue of $211.1 million, a.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a strategic leadership transition of Raj Denhoy, current Chief Financial Officer to Senior Vice President, Global Strategy, and the appointment of Cassandra “Sandra” Harris to Senior Vice President and Chief Financial Officer, effective March 9, 2026. “Over the past.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in TD Cowen's 46th Annual Health Care Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Monday, March 2, 2026 at 9:10 a.m. ET. A live webcast of the presentat.

In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profitability) and short-term price momentum-oriented stocks outperformed. Exact Sciences Corporation received a buyout offer in the fourth quarter by Abbott Laboratories (ABT) for a price of $105 in cash.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, February 24, 2026, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S.

Establishment Labs is transitioning to positive cash flow, ending its cash burn era and justifying its premium valuation. ESTA achieved 20% U.S. breast augmentation market share in under 18 months, outpacing historical competitors and establishing a robust commercial platform. Expansion into the reconstruction segment and minimally invasive procedures is set to double ESTA's addressable market and drive at least 25% annual revenue growth through 2027.

Establishment Labs Holdings Inc. (ESTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced preliminary unaudited financial results for the three months and fiscal year ended December 31, 2025. Establishment Labs' preliminary unaudited revenue for the fourth quarter of 2025 is expected to be in the range of $64.0 million to $65.0 million, including $17.0 m.